John G. McHutchison|Michael P. Manns|Keyur Patel|Thierry Poynard|Karen L. Lindsay|Christian Trépo|Jules L. Dienstag|William M. Lee|Carmen Mak|Jean?Jacques Garaud|Janice K. Albrecht
Adherence to combination therapy enhances sustained response in genotype-1–infected patients with chronic hepatitis C
Duke Medical Center|Clinical Research Institute|Medizinische Hochschule Hannover|Duke Medical Center|Clinical Research Institute|Pitié-Salpêtrière Hospital|Sorbonne Université|University of Southern California|Hôtel-Dieu de Lyon|Massachusetts General Hospital|Harvard University|The University of Texas Southwestern Medical Center
background aims patient adherence prescribed antiviral therapy human immunodeficiency virus infection enhances response evaluated impact adherence combination therapy interferon peginterferon plus ribavirin chronic hepatitis c patients methods assessed effect dose reduction sustained virologic response svr prior trials interferon 2b plus ribavirin n 1010 peginterferon 2b 15 gkgweek plus ribavirin n 511 actual treatment administered verified drug dispensingreturn records patient diaries two groups defined 1 patients received 80 total interferon ribavirin doses 80 expected duration therapy 2 patients received reduced doses 80 one drugs 80 expected duration therapy statistical model provided comparative estimates response rates compliant patients results patients least 80 compliant interferon 2bribavirin peginterferon 2bribavirin therapy svr rates 52 63 respectively 2 regimens apparent hcv1infected patients impacts adherence efficacy subgroup analysis statistical modeling approach similar conclusions hcv1infected patients maintained 80 interferon peginterferon 2b ribavirin dosage duration treatment setting clinical trial exhibit enhanced sustained response rates results suggest adherence enhance likelihood achieving initial virologic response adherence beyond 1224 weeks advantageous patients achieved early virologic responsegastroenterology 200212310611069